An in vivo model for the experimental selection of drugs able to prevent immune complex glomerulonephritis.
Polyclonal activation of lymphocytes and immune complex-mediated glomerular lesions were induced in C57Bl/6 mice by injecting bacterial lipopolysaccharide (LPS) twice a week for 2 weeks. The usefulness of such a model for in vivo evaluation of immunomodulatory and therapeutic effects of drugs, was investigated by treating mice with DIAM4, a cyclophosphazenic compound known to modulate polyclonal activation of lymphocytes and to prevent mouse lupus nephritis. Prevention of LPS-triggered lymphocyte polyclonal activation and glomerular lesions was observed in the DIAM4-treated mice. Such a model can be used conveniently to select compounds effective in the treatment of immune glomerulonephritis.
In
S
S
Laboratoire d'Immunopathologie Rénale et d'Immunopharmacologie, CJF INSERM 88.01, Faculté de Médecine Purpan, Toulouse, France.
Le Lann
A D
AD
Oksman
F
F
Fournié
E L
EL
Labarre
J F
JF
Benoist
H
H
Fournié
G J
GJ
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D001388:Aziridines / Q000627:therapeutic use; D003176:Complement C3 / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005921:Glomerulonephritis / Q000276:immunology / Q000517:prevention & control*; D007105:Immune Complex Diseases / Q000276:immunology / Q000517:prevention & control*; D008070:Lipopolysaccharides / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D009943:Organophosphorus Compounds / Q000627:therapeutic use
D000974:Antibodies, Antinuclear; D001388:Aziridines; D003176:Complement C3; D008070:Lipopolysaccharides; D009943:Organophosphorus Compounds; C050390:DIAM 4